VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.1738
-0.0063 (-3.50%)
At close: Oct 19, 2026, 4:00 PM EDT
0.1735
-0.0003 (-0.17%)
After-hours: Oct 19, 2026, 5:43 PM EDT
VolitionRx Revenue
VolitionRx had revenue of $398.66K in the quarter ending June 30, 2026, a decrease of -1.97%. This brings the company's total for the last twelve months to $2.46M, up 86.32% year-over-year. In the year 2025, VolitionRx had annual revenue of $1.73M with 40.04% growth. That makes VolitionRx the 41,940th largest company in the world by revenue and 5,678th in the United States.
Revenue (ttm)
$2.46M
Revenue Growth
+86.32%
P/S Ratio
1.04
Revenue / Employee
$43,124
Employees
57
Market Cap
2.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73M | 493.87K | 40.04% |
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | 17.10K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 54.97K | - | - |
| Dec 31, 2011 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
| Aug 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| WORK Medical Technology Group LTD | 10.72M |
| Nuwellis | 9.01M |
| Beyond Air | 7.69M |
| INVO Fertility | 7.53M |
| Tenon Medical | 5.31M |
| 20/20 Biolabs | 2.04M |
| Nexalin Technology | 217.16K |
VNRX News
- 4 weeks ago - VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France - PRNewsWire
- 4 weeks ago - VolitionRx Participates in Launch of DETECSEPS Program in France - PRNewsWire
- 5 weeks ago - VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 - PRNewsWire
- 5 weeks ago - VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference - TheFly
- 5 weeks ago - Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference - PRNewsWire
- 5 weeks ago - VolitionRx Slides: Corporate presentation - Filings
- 5 weeks ago - VolitionRx Registration statement: Registration filing - Filings
- 5 weeks ago - VolitionRx Registration statement: Registration filing - Filings